Literature DB >> 28467444

Human cytomegalovirus glycoprotein polymorphisms and increasing viral load in AIDS patients.

Xiao-Jing Jiang1, Jun Zhang2, Yong Xiong3, Gerhard Jahn4, Hai-Rong Xiong5, Zhan-Qiu Yang5, Yuan-Yuan Liu5.   

Abstract

BACKGROUND: Multiple strains infection of human cytomegalovirus (HCMV) was found to be correlated with increased viral load in immunodeficient patients. However, the pathogenic mechanism underlying this correlation remains unclear. To evaluate genetic polymorphisms of HCMV glycoprotein and their potential role in its viral load, HCMV glycoprotein B, N, and O (gB, gN and gO) genotypes was studied in the population of HCMV infected acquired immune deficiency syndrome (AIDS) patients. The association between glycoprotein polymorphisms and HCMV viral load was analyzed.
METHODS: The genetic polymorphisms of glycoprotein from sera of 60 HCMV infected AIDS patients was investigated by multiplex nested PCR and sequencing. HCMV viral load was evaluated by quantitative PCR.
RESULTS: gB1, gO1a, and gN4a were the predominant glycoprotein genotypes in HCMV infected AIDS patients and composed 86.96%, 78.8%, and 49.2%, respectively. Only gN4a genotype infection significantly increased viral load (P = 0.048). 71% (43/60) of HCMV infected AIDS patients were found to carry multiple HCMV strains infection. A novel potential linkage of gO1a/gN4a was identified from multiple HCMV infected patients. It was the most frequent occurrence, accounted for 51.5% in 33 patients with gO and gN genotypes infection. Furthermore, the gO1a/gN4a linkage was correlated to an increased viral load (P = 0.020).
CONCLUSION: The gN4a correlates to higher level HCMV load in AIDS patients. Interestingly, a novel gO1a/gN4a linkage is identified from the patients with multiple HCMV strains infection and is also associated with an increased viral load. Therefore, the pathogenic mechanism underlying glycoprotein polymorphisms and interaction of variants should be analyzed further.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28467444      PMCID: PMC5415198          DOI: 10.1371/journal.pone.0176160

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Human cytomegalovirus (HCMV), a member of the herpesvirus family, infects 50–100% of adults worldwide. The primary infection is often acquired during early childhood and later persists lifelong in a latent stage. It is usually asymptomatic in immunocompetent individuals infected with HCMV. However, reactivate or exogenous reinfection with HCMV may occur and become a major viral cause of morbidity and mortality in immunocompromised patients such as Acquired Immune Deficiency Syndrome (AIDS) patients and stem cell-transplant recipients. In immunodeficient patients, the occurrence and severity of HCMV disease generally are often associated with the grade of immunosuppression. It also may correlate with host susceptibility factors and HCMV strain virulence. The difference of HCMV virulence between different HCMV strains is due to their genetic variants [1], such as their variation in HCMV encoded envelope glycoprotein B (gB), gM, gN, gH, gL, and gO. These glycoproteins are involved in virus entry, egress, transmission and are major targets of immune responses [1-6]. Different levels of variation of glycoprotein genes were observed in HCMV clinical isolates and laboratory adapted strains. Except that the gH and gM genes were highly conserved. The gN and gO genes have hypervariation locus, which account for 40–50% in the level of variation [7]. The gB and gH genes present a modest variation (5–11%) [8, 9]. According to the sequence variation of UL55 gene that encodes gB, there are four major gB genotypes(gB1, gB2, gB3, gB4) [10-13]. In addition, three nonprototypic genotypes (gB5, gB6, gB7) have been identified [14] [15]. Previous studies showed that gB2 is the predominant gB type in AIDS patients [11–13, 16, 17]. However, the association of gB genotypes and disease progression is still controversial. The UL73 encodes gN, which shows four genotypes (gN1, gN2, gN3, and gN4). The gN3 genotype includes two subgenotypes (gN3a and gN3b) and gN4 includes three subgenotypes (gN4a, gN4b, and gN4c) [7, 18, 19]. The UL74 encodes gO and five major genotypes (gO1, gO2, gO3, gO4 and gO5) with minor subtypes (gO1a, gO1b, gO1c, gO2a, gO2b) have been defined in the gO gene [10, 20]. Despite high variation locus at gO and gN genes, the biological meaning of the variation is largely unknown. Recently seven linkages between the gO and gN genotypes have been defined. They are gO1a/gN1, gO1b/gN3a, gO1c/gN4c, gO2a/gN3b, gO2b/gN2, gO3/g4a, and gO4/gN4b [21]. However, the effect of these gO/gN linkages on HCMV virulence is not clearly understood. gN forms a complex with gM (gM/gN) and gO forms a complex with gH/gL (gH/gL/gO), and these two complexes play an essential role in viral entry, transmission and exit. We hypothesize that there is interaction between the complex of gM/gN and gH/gL/gO, which may have impact on virulence of HCMV and is associated with clinical outcomes. To assess the effect of HCMV glycoprotein polymorphisms on viral virulence, a cohort of Chinese AIDS patients were selected for the study. We investigated the distribution of gB, gO, and gN genotypes and their correlation with viral load in these patients. We aslo investigated the association between different gO/gN linkage groups and viral load.

Materials and methods

Patients and data collection

Blood samples were obtained from 106 hospitalized AIDS patients with CD4+ count < 100 cells/mm3 during the period of May 2012 to May 2014 at the department of infectious diseases, Zhongnan Hospital of Wuhan University, China. Ethical approval for the study was obtained from the Research Ethics Committee of Wuhan University. All the patients were informed the consent of the study and signed statement before starting the research work. The clinical data were registered, including gender, age, current HIV treatment, CD 4+ counts, and opportunistic infections (Table 1). All the patients had not received any antiherpesvirus treatment before they participated in this study.
Table 1

Characteristics of AIDS patients with and without detectable HCMV IE4 gene in serum samples.

CharacteristicsHCMV positive (n = 65)HCMV negative (n = 41)
Gender
Male4731
Femal1810
Age (Mean±SD)40.0±12.336.5±12.0
Current HIV treatment
Yes2015
No4526
Mean CD4+ counts, cells/ mm317.027.0
Opportunistic infections
Toxoplasmosis11
Tuberculosis1649
Cryptococcosis37
Pneumocystosis41
fungal infection3115
        HCMV retinitis96
        HCMV encephalitis20
    HCMV colitis113

HCMV DNA isolation and detection

Sera from patients were used for DNA isolation.DNA was extracted from sera using AxyPrepTM body Fluid Viral DNA/RNA Miniprep Kit (Axygen, USA). The nested PCR was used to amplify HCMV IE4 gene in the sera samples. The primers for amplification and PCR procedure were identical to our previous study [22]. Samples determined to be HCMV DNA positive were further examined for genotyping and viral load. The real-time quantitative PCR with SYBR GREEN (Toyobo, Japan) was carried out for detection of HCMV DNA load as described previously [23]. The primers for quantitative PCR were designed by Premier 5.0 software and listed in Table 2. The CT values obtained for the samples were plotted on the standard curve and then the copy number was calculated. The HCMV DNAs were defined as negative when the CT values exceeded 40 cycles.
Table 2

Primers used for multiplex nested PCR, real-time PCR and gN sequencing.

GeeMethodPrimerPrimer sequence (5’ to 3’)GenBank accessionPositionProduct length
gBPrimary PCRUL55 upTTTGGAGAAAACGCCGACKP745727.183930 to 83947751
UL55 lowCGCGCGGCAATCGGTTTGTTGTAKP745727.183196 to 83218
Nested PCRgB1ATGACCGCCACTTTCTTATCKF297339.184086 to 84105420
gB2TTCCGACTTTGGAAGACCCAACGFJ527563.183509 to 83531613
gB3TAGCTCCGGTGTGAACTCCGU937742.183097 to 83115190
gB4ACCATTCGTTCCGAAGCCGAGGAGTCAGU179291.183557 to 83579465
gB5TACCCTATCGCTGGAGAACAF062421.178 to 96139
gB lowGTTGATCCACRCACCAGGCKP745727.183284 to 83302
gNPrimary PCRUL73 upAGTCGATTCGGTCGGTCAACKP745723.1106325 to 106344469
UL73 lowCCACCCTCAATAGCCTTTGGTKP745723.1106767 to 106787
Nested PCRgN 1TTCTGCTAGCGTATCAACTACCFJ527563.1106796 to 106817283
gN 2AGTGCAAAACACTGGTGCTGU179291.1106907 to 106925380
gN 3bCACAACCACATTAACGAGTX512202.1106738 to 106756214
gN 4aCAACAATACGTCGACTGCTAGCACACAY446894.2107107 to 107132325
gN 4b/cGACAACTAGTACAACTACGGTGACAAFJ616285.1106421 to 106446244
gN lowGACATTGCTGCTTCCAGAAKP745723.1106732 to 106750
gOPrimary PCRUL74 upTGGTGTGATGGAGTGGAACKP745727.1107053 to 1070711901
UL74 lowAACGGTAGATGAGCAGCAAAACGACKP745727.1108930 to 108954
Nested PCR(Group 1)gOup-1GCTCATGGCGTTAACCAGGTAKP745727.1108144 to 108164
gO1a-2ATAATCGTCCTTGGAGGGGCFJ527563.1108349 to 108368582
gO 2aACTGTTAATATGACCGAGTTTCCTEU348354.1244 to 267441
gO 3TCAAACAGGCCGAAAGATGAAF531318.1393 to 412304
gO 4ACTGCAAGAACTAGCGTCAAFJ616285.1107859 to 107878520
gO 5CAGTACTCAACTCCGAAAACCAAY446894.2108468 to 108489352
Nested PCR(Group 2)gO up-2:GCTCATGGCGTTAACCAGGKP745727.1108144 to 108162
gO 1a-1TAATCGTCCTTGGAGGGGCTFJ527563.1108348 to 108367581
gO 1bGTAGGGCTGCGGTAAGATTATAF531354.186 to 106608
gO 1cAGGCAACACGTTAAAAATCTTACTKF297339.1108979 to 109002462
gO 2bATAATCAAACGGCTCAGAAAATCAGU179288.1108357 to 108380308
IEreal-time PCRP15’-TTTAGCACGGGCCTTAGCCT-3’FJ527563.1172849 to 17286876
P25’-GCTGCATGATGTGAGCAAGGG-3’172898 to 172918
gNsequencinggN up5’-TGGTGTGTGATGGAGTGGAAC-3’KP745722.1106845 to 106861417
gN low5’-TAGCCTTTGGTGGTGGTTGC-3’107243 to 107262

* The multiplex nested PCR assay was performed for genotyping. The first PCR round was designed to amplify the segment containing the major variable region of target gene. The primers for primary PCR were designed on the conserved regions. The nested PCR round was carry out with a set of genotype-specific primers. For gB/gN genotyping, the multiplex nested PCR was performed using a set of genotype-specificprimers (gB1, gB2, gB3, gB4, gB5/ gN1, gN2, gN3b, gN4a, gN4b/c) and a single common primer (gB low/ gN low), respectively. For detection of gO genotypes, the multiplex nested PCR was divided into 2 groups. The gO up-1 was used as the common primer and a set of genotype-specific primers (gO1a-2, gO2a, gO3, gO4, gO5) was used to distinguish five gO genotypes in group1. In group2, the gO up-2 was used as the common primer and gO1a-1, gO1b, gO1c, gO2b were used as the genotype-specificprimers.

* The multiplex nested PCR assay was performed for genotyping. The first PCR round was designed to amplify the segment containing the major variable region of target gene. The primers for primary PCR were designed on the conserved regions. The nested PCR round was carry out with a set of genotype-specific primers. For gB/gN genotyping, the multiplex nested PCR was performed using a set of genotype-specificprimers (gB1, gB2, gB3, gB4, gB5/ gN1, gN2, gN3b, gN4a, gN4b/c) and a single common primer (gB low/ gN low), respectively. For detection of gO genotypes, the multiplex nested PCR was divided into 2 groups. The gO up-1 was used as the common primer and a set of genotype-specific primers (gO1a-2, gO2a, gO3, gO4, gO5) was used to distinguish five gO genotypes in group1. In group2, the gO up-2 was used as the common primer and gO1a-1, gO1b, gO1c, gO2b were used as the genotype-specificprimers.

Genotyping

For the HCMV DNA positive samples, the multiplex nested PCR assay was used for gB, gN and gO genotyping. The primers are listed in Table 2. For gB and gN genotyping, the PCR assays were operated as described by Tarragó [17] and Pignatelli [24]. The gN genotyping results were further confirmed by PCR and sequencing. For gO genotyping, due to the complexity of the gO genotype, the multiplex PCR was divided into 2 groups. The one group was designed to distinguish five gO genetypes (gO1a, gO2a, gO3, gO4, gO5), the other one was to genotype gO1a, gO1b, gO1c, gO2b. The first PCR round condition was 95°C for 5min and 34 cycles of 94°C for 1min, 57°C for 1min, 72°C for 1min, and a final elongation at 72°C for 10 min. In the second round, the annealing temperature of the nest PCR for group 1 and group 2 was 58°C, others conditions were as same as the first round. All the reactions of PCR were performed in 50μl volume containing 25μl of Premix Tag (TAKARA), 5 μl DNA, 20pmol primers and H2O. HCMV DNA sample from HCMV AD 169 strain was used as positive control and distilled water was used as negative control. Then the gB, gN and gO genotypes were differentiated by agarose gel electrophoresis.

DNA sequencing and sequences analysis

Genotyping of gN was also achieved by DNA sequencing. The products of PCR were purified (QIAquick PCR Purification Kit, Qiagen) and sequenced by Sangon Biotech (Shanghai, China) Co.Ltd. The primers are listed in Table 2. Data were assembled manually and edited by ClustalX 2.0 and MEGA 5.1 software.

Statistical analyses

All statistical analysis was performed using SPSS Statistics 20.0 (IBM, USA). Continuous variables were compared between 2 groups by the independent samples t-test for normally distributed or Mann-Whitney U-test for non-normally distributed variables. Two-tailed P values of below 0.05 were considered significant.

Results

Frequency of mixed HCMV infection with multiple gB, gO and gN genotypes in AIDS patients

The quantitative PCR was conducted to detect HCMV DNA from blood samples of 106 patients with AIDS. 61.3% (65/106) of patients were HCMV DNA positive. Only 60 out of these 65 HCMV infected AIDS patients had gB, gO or gN genotyping data. 71% (43/60) of patients were found to carry mixed infections with multiple genotypes in at least one genetic locus of gB, gO and gN.

Distribution of gB, gO and gN genotypes in HCMV infected AIDS patients

The gel electrophoresis of multiplex nested PCR products was performed for distinguishing genotypes of gB, gO and gN (Fig 1, S1 Table).
Fig 1

Multiplex nested PCR analysis for identification of HCMV gB, gN, gO genotypes (AD 169 is HCMV laboratory strain).

A) Multiplex nested PCR analysis for HCMV gB genotyping. Size: gB1, 420bp; gB2, 613bp; gB3, 190bp; gB4, 465bp; gB5, 139bp. AD-169 (gB2); Sample (gB1+ gB3+gB4). B) Multiplex nested PCR analysis for HCMV gN genotyping. Size: gN1, 283bp; gN2, 380bp; gN3 214bp; gN4a, 325bp, gN4b/c, 244bp. AD-169 (gN1); Sample (gN1+gN2+gN3b). C-1) Multiplex nested PCR analysis for HCMV gO genotyping (Group1). Size: gO1a, 582bp; gO2a, 441bp; gO3 304bp; gO4, 520bp; gO5, 352bp. AD-169 (gO1a); Sample (gO3). C-2) Multiplex nested PCR analysis for HCMV gO genotyping (Group2) Size: gO group2: gO1a, 581bp; gO1b, 608bp; gO1c, 462bp; gO2b, 308bp. AD-169 (gO1a); Sample (gO1a+gO1c).

Multiplex nested PCR analysis for identification of HCMV gB, gN, gO genotypes (AD 169 is HCMV laboratory strain).

A) Multiplex nested PCR analysis for HCMV gB genotyping. Size: gB1, 420bp; gB2, 613bp; gB3, 190bp; gB4, 465bp; gB5, 139bp. AD-169 (gB2); Sample (gB1+ gB3+gB4). B) Multiplex nested PCR analysis for HCMV gN genotyping. Size: gN1, 283bp; gN2, 380bp; gN3 214bp; gN4a, 325bp, gN4b/c, 244bp. AD-169 (gN1); Sample (gN1+gN2+gN3b). C-1) Multiplex nested PCR analysis for HCMV gO genotyping (Group1). Size: gO1a, 582bp; gO2a, 441bp; gO3 304bp; gO4, 520bp; gO5, 352bp. AD-169 (gO1a); Sample (gO3). C-2) Multiplex nested PCR analysis for HCMV gO genotyping (Group2) Size: gO group2: gO1a, 581bp; gO1b, 608bp; gO1c, 462bp; gO2b, 308bp. AD-169 (gO1a); Sample (gO1a+gO1c). The gB genotype was successfully determined from 76.7% (46/60) of HCMV infected AIDS patients. The genotype gB1 was predominant and composed 87.0% (40/46) of patients, followed by gB3 in 60.9% (28/46), gB2 in 19.6% (9/46), gB4 in 17.4% (8/46), gB5 in 13.0% (6/46). The gO genotype was determined from 55% (33/60) of HCMV infected AIDS patients. The gO1a was predominant and composed 78.8% (26/33) of patients, followed by gO3 in 39.4% (13/33), gO2b in 24.2% (8/33), gO1c in 15.2% (5/33), gO2a and gO5 in 12.1% (4/33), respectively, and gO1b in 3.0% (1/33). The gN genotype was determined from 98.3% (59/60) of HCMV infected AIDS patients. The gN4a was predominant and accounted for 49.2% (29/59) of patients, followed by gN2 in 45.8% (27/59), gN1 in 28.8% (17/59), gN3b in 23.7% (14/59), gN4b in 10.2% (6/59), gN3a in 8.5% (5/59), and gN4c in 5.1% (3/59).

Analysis of predominant glycoprotein genotypes and viral load in HCMV infected AIDS patients

Comparison of viral load between the groups with and without gB1 infection showed that no significant difference was observed. In addition, no significant difference was found regarding viral load between groups with and without gO1a infection. Interestingly, the viral load of patients with gN4a infection was significantly higher than patients without gN4a infection (P = 0.048). Other genotypes were also analyzed, but no significant difference was found regarding to viral load. Data are shown in Fig 2A and 2B, Table 3 and S1 Table.
Fig 2

Comparison of HCMV viral load as measured by real-time quantitative PCR in blood samples and distribution of glycoprotein genotypes gO and gN genotypes in AIDS patients.

A) The difference between the viral load within groups presence and absence of gO1a was not statistically significant (P = 0.062); B) The difference between the viral load within groups with and without gN4a was statistically significant (P = 0.048); C) The difference between the viral load within groups presence and absence of gO1a and gN4a was statistically significant (P = 0.020).

Table 3

HCMV viral load in patients with presence and absence of gO1a and gN4a genotype infection.

gO1a(n)gN4a(n)
Presence (24)Absence (26)P ValuePresence (27)Absence (23)P Value
Viral load (log10 copies/ml)2.4(1.8–3.0)1.9(1.3–2.6)0.0622.4(1.7–3.0)1.9(1.2–2.5)0.048

Values are given as median (interquartile range).

Comparison of HCMV viral load as measured by real-time quantitative PCR in blood samples and distribution of glycoprotein genotypes gO and gN genotypes in AIDS patients.

A) The difference between the viral load within groups presence and absence of gO1a was not statistically significant (P = 0.062); B) The difference between the viral load within groups with and without gN4a was statistically significant (P = 0.048); C) The difference between the viral load within groups presence and absence of gO1a and gN4a was statistically significant (P = 0.020). Values are given as median (interquartile range).

Analysis of genetic linkage of gO/gN variants in multiple HCMV strains infected AIDS patients

Both gO and gN genotypes were identified from 33 patients with multiple HCMV strains infected AIDS patients. In the investigated sera, only 5 patients with single genotype in both gO and gN infection were found. Two sera samples contained indentified genetic linkage of gO1a/gN1 and the other three samples contained gO1a/gN4a, gO1a/gN3b and gO1a/gN2. Sera of 28 patients contained multiple genotypes in at least one genetic locus of gO and gN. The association of gO1a and gN4a was the most frequent appearance in all these samples and accounted for 51.5% (17/33). The linkage of gO1a/gN4a was a new observation in this study and has not been described previously [21]. Other associations of gO and gN were observed as gO1a/gN1 in 30.3% (10/33), gO3/gN4a in 27.3% (9/33), gO2b/gN2 in 9.1% (3/33), gO1b/gN3a, gO2a/gN3b, and gO4/gN4b in 3.0% (1/33), respectively. The percentage of all association of gO and gN in multiple HCMV strains infection patients is shown in Table 4 and Fig 3.
Table 4

Association of gO and gN genotypes in multiple HCMV infection.

gO
gN1a(n = 26)1b(n = 1)1c(n = 5)2a(n = 4)2b(n = 8)3(n = 13)4(n = 2)5(n = 4)
1(n = 11)10(30.3)0(0)1(3.0)1(3.0)3(9.1)4(12.1)1(3.0)0(0)
2(n = 17)13(39.4)1(3.0)4(12.1)1(3.0)3(9.1)8(24.2)0(0)3(9.1)
3a(n = 2)1(3.0)1(3.0)1(3.0)1(3.0)0(0)1(3.0)0(0)1(3.0)
3b(n = 6)3(9.1)0(0)0(0)1(3.0)2(6.1)3(9.1)0(0)0(0)
4a(n = 21)17(51.5)1(3.0)3(9.1)3(9.1)4(12.1)9(27.3)2(6.1)4(12.1)
4b(n = 4)4(12.1)0(0)0(0)1(3.0)2(6.1)0(0)1(3.0)0(0)
4c(n = 2)1(3.0)0(0)0(0)0(0)0(0)1(3.0)0(0)0(0)

Data are expressed as number (%) of patients.

Fig 3

Distribution of different gO/gN linkages in AIDS patients with multiple HCMV genotypes infection.

Data are expressed as number (%) of patients.

Analysis of gO/gN genotype and viral load

In order to study the effects of gO/gN genotype linkages on HCMV viral load, the independent samples t-test was performed. The linkages of the certain gO/gN genotypes (gO1a/gN1 and gO3/gN4a) were not associated with the viral load. However, the presence of gO1a/gN4a linkage group showed a significant higher viral load compared with the absence of the gO1a/gN4a linkage group (2.6±1.2 vs 1.8±1.0, P = 0.020), Data was shown in Table 5 and Fig 1C. The correlation of previous defined linkages of gO2b/gN2, gO4/gN4b and viral load were not analyzed because of the limited sample numbers.
Table 5

Association between gO/gN genotype linkages and viral load.

gO1a/gN4a(n)*gO1a/gN1(n) *gO3/gN4a(n) *
Presence (16)Absence# (34)P ValuePresence (9)Absence# (41)P ValuePresence (9)Absence# (41)P Value
Viral load (log10 copies/ml)2.7(1.9–3.1)2.0(1.3–2.6).0202.4(0.7–2.9)2.2(1.5–2.7)NS1.9(0.9–3.3)2.3(1.6–2.7)NS

* Values are given as median (interquartile range).

# Absence of all the corresponding gO and gN genotypes.

NS: none significance.

* Values are given as median (interquartile range). # Absence of all the corresponding gO and gN genotypes. NS: none significance.

Discussion

In the present study on AIDS patients in Wuhan, the prevalence of HCMV DNA in blood samples was frequently found in up to 61.3%. And mixed HCMV infection with multiple glycoprotein (gB, gO and gN) genotypes was found in 71% of HCMV infected AIDS patients with CD4 count < 100/mm. Previous studies demonstrated that HCMV viremia increases mortality in AIDS patients with low CD4 counts [25, 26]. In addition, multiple HCMV infection was correlated with lethal outcome of fetus during pregnancy [27], higher viral load, delayed virus clearance, and higher rate of virus recurrency after antiviral treatment in transplant recipients and AIDS patients [20, 28]. However, little is known with respect to what factors determine HCMV virulence in the time course of infection and the grade of the host immune status. Most of the HCMV genome is conserved both in laboratory and clinical strains. However, encoding viral glycoprotein genes, such as gB, gH, gN and gO are known to be variable sequences and may play crucial roles in HCMV cell tropism and in elicitation of neutralizing antibodies by interaction with host’s immune system[4, 29]. Previous studies have shown that glycoprotein genes are quite stable during long term of infection course in hosts [30]. This implicates that certain polymorphisms might be associated with strain-specific features, such as tissue tropism, virulence, and HCMV-induced immunopathogenesis. However, number of investigations about the relationship of glycoprotein genotypes and HCMV pathogenicity in AIDS patients showed controversial results. For instance, gB2 was observed being a predominant genotype in HIV/AIDS patients, but its association with HCMV retinitis yielding conflicting results [16, 31, 32]. The distribution of the gO genotypes in clinical isolates from different geographic regions and different disease settings demonstrated that no clear correlation exists between gO genotype and HCMV disease [20, 21, 33]. The gN4b was found associated with higher level of antigenemia in solid organ transplant recipients [34]. The gN1 and gN3a were shown associated with a more benign course of congenital HCMV infection and gN4 correlated to increased incidence of sequelae [35]. However, gN genotyping analysis evaluated in a large number of adult SOT recipients and hematopoietic stem cell transplant recipients showed that no single genotype of gN correlated with clinical features[36, 37]. Therefore, the effects of glycoprotein polymorphisms on pathogenesis of HCMV infection are largely unknown. Since high HCMV viral load levels are significantly associated with death, independently of CD4 counts, other opportunistic infections and highly active antiretroviral therapy (HAARDT) in AIDS patients [25, 38, 39], Therefore, we choose viral load as indicator of HCMV virulence. For understanding the biological role of glycoprotein gene polymorphisms for HCMV virulence, the current study investigated the association between the distribution of gB, gO, gN genotypes and the viral load in blood. Our study clearly demonstrated that the genotype gB1 was predominant and composed 86.96% of patients. This is in contrast to the predominant distribution of gB2 in AIDS patients and may associate with higher viral load and retinitis [11, 31, 32]. gO1a and gN4a were the other two predominant genotypes in our cohort, composed 78.8% and 49.2% of patients, respectively. Although gB1 and gO1a were predominant genotypes, they do not have an impact on HCMV viral load compared to other gB and gO genotypes. Interestingly, gN4a is significantly associated with higher-level of viral load (P = 0.048), which suggests that gN4a may play a role in virulence of HCMV in AIDS patients. Based on the discrepancy with regard to the distribution of gB, gO and gN genotypes in different clinical settings and the virulence relation with certain gB, gO and gN genotypes in our study and in previous reports, we assume that virulence of HCMV may be dependent on synergistic action by at least two glycoproteins of HCMV. Previous studies illustrated no clear genetic linkages between gB and gN, gH and gO, gH and gN, gO and gH, gO and gL genotypes [7, 19, 20, 40], respectively. In contrast, the analysis of gO and gN genotypes in both laboratory strains and clinical isolates from congenitally infected newborns, transplant recipients and HIV/AIDS patients from Caucasian populations and Japanese infants illustrated that eight consistent linkages could be indentified between hypervariable gO and gN genotypes as follows: gO1a/gN1, gO1b/gN3a, gO1c/gN4c, gO2a/gN3b. gO2b/gN2, gO3/gN4a,gO4/gN4b, gO5/gN4c [21, 40]. Underlining the relationship of gO/gN linkages and HCMV disease, gO1a/gN1 was observed initially having an association with HCMV disease in HIV/AIDS patients and in congenital infections [19, 41]. Therefore, the linkage of gO/gN genotypes may have a potential functional interaction between these glycoproteins with their corresponding complexes, gC-II (gM/gN) and gC-III (gH/gL/gO). These complexes play a role in attachment, replication and spread of HCMV. In summary, in the present study a novel potential linkage of gO1a/gN4a was identified. The gO1a/gN4a was the most frequent detected glycoprotein linkage (51.5%) in HCMV infected AIDS patients and was significantly associated with higher level of viral load compared to other defined gO/gN linkages, despite gO1a alone didn’t correlate to the level of viral load. The phenotype of a gO deletion mutant reveals that gO plays a critical role in secondary envelopment and is required for cell-to-cell transmission in fibroblasts [42]. The gO can bind to gH/gL forming gH/gL/gO complex [43, 44] which promotes the virus entry into various cell types [45]. Concerning the previous studies about the function of gO, our analyses imply that the genetic linkage between gO1a and gN4a may have a functional interaction, which possible contribute to virus replication, entry and cell tropism. The synergistic action by gO and gN, specifically by gO1a and gN4a may play an important role in virulence of HCMV. Therefore, the relationship of gO1a /gN4a and HCMV disease in AIDS patients should be taken into account. In contrast to the previous studies [19, 41], no association was observed between gO1a/gN1, gO3/gN4a and viral load, which may be due to limited sample numbers in this study. Up to now, we don’t really understand how different HCMV strains interact with each other and what the biological significance of this interaction could be, particularly in immunedeficient patients, even though mixed HCMV strain infection showed disadvantageous for these patients. Either the formation of matched gO/gN genotypes due to recombinant virus induced by recombination of glycoprotein genes between two virus strains or due to interactions by different strains during mixed infection, is an important question. Several previous studies analyzed sequences from HCMV clinical isolates and laboratory-adapted strains and showed that genomic rearrangements and deletions occurred for giving added functions to immunomodulation or infectivity of HCMV [46-48]. In addition, the location between the gO and gN genes is a major site for rearrangements between herpesvirus lineages [49]. It suggests that some recombinations may occur between gO/gN sub-groupings in the infected host. However, perivous study in the murine model infected with two distinct MCMV strains, demonstrated that coinfection just alters virus fitness by functional trans-complementation rather than by genetic recombination [50]. Therefore, how synergistic contribution of variants which enhance HCMV pathogenicity in the multiple HCMV infected host, needs further investigation.

Conclusion

The multiple HCMV strain infection is quite frequent in advanced AIDS patients. Although the genotype gB1, gO1a, and gN4a of HCMV are the predominant glycoprotein genotypes infection, only gN4a is correlated to higher level of viral load. Moreover, a novel gO1a/gN4a linkage is identified, which is associated with an increased viral load. Therefore, the pathogenic mechanisms underlying glycoprotein polymorphisms and the interaction of virus variants are needed to further study.

Viral load of all patients with respective genotypes.

This is the raw data file for all analyses. (DOC) Click here for additional data file.
  50 in total

Review 1.  Molecular pathogenesis of human cytomegalovirus infection.

Authors:  L Rasmussen
Journal:  Transpl Infect Dis       Date:  1999-06       Impact factor: 2.228

2.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Human cytomegalovirus glycoprotein N genotypes in AIDS patients.

Authors:  Sara Pignatelli; Giada Rossini; Paola Dal Monte; Maria R Gatto; Maria P Landini
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

4.  Cytomegalovirus gN genotypes distribution among congenitally infected newborns and their relationship with symptoms at birth and sequelae.

Authors:  Sara Pignatelli; Tiziana Lazzarotto; Maria R Gatto; Paola Dal Monte; Maria P Landini; Giacomo Faldella; Marcello Lanari
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

5.  Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes.

Authors:  S W Chou; K M Dennison
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

6.  A role for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable locus.

Authors:  David A Paterson; Angela P Dyer; Richard S B Milne; Edgar Sevilla-Reyes; Ursula A Gompels
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

7.  Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients.

Authors:  S A Spector; R Wong; K Hsia; M Pilcher; M J Stempien
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Development of a multiplex PCR for the simultaneous amplification and genotyping of glycoprotein N among human cytomegalovirus strains.

Authors:  Sara Pignatelli; Daniela Maurizio; Maria Paola Ladini; Paola Dal Monte
Journal:  New Microbiol       Date:  2010-07       Impact factor: 2.479

9.  gpUL73 (gN) genomic variants of human cytomegalovirus isolates are clustered into four distinct genotypes.

Authors:  S Pignatelli; P Dal Monte; M P Landini
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

Review 10.  Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains.

Authors:  Sara Pignatelli; Paola Dal Monte; Giada Rossini; Maria Paola Landini
Journal:  Rev Med Virol       Date:  2004 Nov-Dec       Impact factor: 6.989

View more
  6 in total

1.  Human Cytomegalovirus Glycoprotein-Initiated Signaling Mediates the Aberrant Activation of Akt.

Authors:  Jamil Mahmud; Michael J Miller; Aaron M Altman; Gary C Chan
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

2.  Complexity of Human Cytomegalovirus Infection in South African HIV-Exposed Infants with Pneumonia.

Authors:  Kerusha Govender; Raveen Parboosing; Salvatore Camiolo; Petr Hubáček; Irene Görzer; Elisabeth Puchhammer-Stöckl; Nicolás M Suárez
Journal:  Viruses       Date:  2022-04-21       Impact factor: 5.818

3.  Human cytomegalovirus and Epstein-Barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure.

Authors:  Jianhua Hu; Hong Zhao; Danfeng Lou; Hainv Gao; Meifang Yang; Xuan Zhang; Hongyu Jia; Lanjuan Li
Journal:  BMC Infect Dis       Date:  2018-11-16       Impact factor: 3.090

Review 4.  Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases.

Authors:  Jean de Melo Silva; Renato Pinheiro-Silva; Anamika Dhyani; Gemilson Soares Pontes
Journal:  Biomed Res Int       Date:  2020-10-24       Impact factor: 3.411

Review 5.  Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity.

Authors:  Hsuan-Yuan Wang; Sarah M Valencia; Susanne P Pfeifer; Jeffrey D Jensen; Timothy F Kowalik; Sallie R Permar
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.818

6.  Cytomegalovirus Glycoprotein Polymorphisms and Increasing Viral Load in Non-Transplant Patients with Hematological Malignancies Undergoing Chemotherapy: A Prospective Observational Study.

Authors:  Imene Handous; Naila Hannachi; Bechir Achour; Manel Marzouk; Olfa Hazgui; Abderrahim Khelif; Jalel Boukadida
Journal:  Infect Dis Ther       Date:  2021-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.